Neopharm Boston Competitors and Similar CompaniesClear all

Neopharm Boston's competitors and similar companies include Fortrea, Pfizer, Novartis and ArQule.

	Neopharm Boston Neopharm Boston (formerly Averica Discovery Services) is an analytical development contract research organization.	Fortrea Fortrea Holdings (formerly known as Labcorp Clinical Development and Commercialization Services) is a contract research organization (CRO).	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.
Founding Date	Founding Date 2007	Founding Date 2023	Founding Date 1849	Founding Date 1996	Founding Date 1993
Type	Type Subsidiary	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Marlborough, US HQ	Locations Durham, US HQ Buenos Aires, AR Melbourne, AU Sydney, AU Zaventem, BE Sao Paulo, BR Sofia, BG see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations Burlington, US HQ
Employees	Employees 717% increase	Employees 19,000	Employees 81,0008% decrease	Employees 75,883	Employees 3613% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 1.6 b	Valuation ($) 163.9 b	Valuation ($) N/A	Valuation ($) 2.4 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $2.7b (FY, 2025)	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $16.1b (FY, 2025)	Cost of goods $8.4b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $46.5b (FY, 2025)	Gross profit $49.8b (FY, 2025)	Gross profit N/A
Net income	Net income N/A	Net income ($986.2m) (FY, 2025)	Net income $7.8b (FY, 2025)	Net income $14b (FY, 2025)	Net income ($15.5m) (FY, 2018)
Operating ⚠
Countries	Countries N/A	Countries 90 (Jul, 2023)	Countries 200 (FY, 2024)	Countries N/A	Countries N/A
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 32 (FY, 2024)	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products N/A
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products N/A	Registration Phase Products 5 (FY, 2024)	Registration Phase Products 8 (FY, 2022)	Registration Phase Products N/A